Delivery Format Science · Xynaptic Drops™ · nutropx.com/science

Liposomal Delivery

How Lipid-Bilayer Encapsulation Works — And What It Means for Xynaptic Drops™

Liposomes are microscopic spherical structures formed from phospholipid bilayers — the same class of lipid molecule that makes up natural cell membranes. Liposomal delivery encapsulates an active ingredient within these lipid spheres, offering an alternative to capsule or tablet formats. In Xynaptic Drops™, Cognizin® citicoline is delivered within a liposomal bilayer constructed from sunflower lecithin. This page explains what that means scientifically, and where we draw the line on what can and cannot be claimed for it.

Established lipid-vesicle technology Sunflower lecithin source Soy free · Non-GMO Used in Xynaptic Drops™

First described

1965

Bangham, Babraham Institute

Bilayer thickness

~5 nm

Approximate phospholipid bilayer

Lipid source

Sunflower

Lecithin / phosphatidylcholine · Soy free

First FDA-approved liposomal drug

1995

Doxil (doxorubicin) · Established pharma technology

What is a liposome?

A liposome is a microscopic spherical structure composed of one or more phospholipid bilayers surrounding an aqueous interior. The same kind of molecule — phospholipid — that makes up the membranes around every cell in your body. When phospholipids are dispersed in water under the right conditions, they spontaneously self-assemble into bilayer spheres because of the dual nature of the molecule: each phospholipid has a hydrophilic (water-loving) head and two hydrophobic (water-fearing) fatty acid tails.

The result is a structure where the hydrophilic heads face outward (in contact with water) on both sides of the membrane, while the hydrophobic tails point inward toward each other, away from water. The interior cavity of the liposome is aqueous — meaning water-soluble compounds can be encapsulated inside it.

Cross-section of a liposome with encapsulated Cognizin® citicoline

Schematic representation. Liposomes are typically 50–500 nanometers in diameter — about 1,000× smaller than a human hair. The phospholipid bilayer is approximately 5 nanometers thick. Diagram is not to scale.

Phospholipid head (hydrophilic)

Fatty acid tails (hydrophobic)

Encapsulated Cognizin®

Aqueous core (water)

Liposomes were first described by Alec Bangham at the Babraham Institute in 1965, when he observed that phospholipids spontaneously formed closed bilayer spheres in water. The first FDA-approved liposomal pharmaceutical (Doxil, a liposomal form of doxorubicin) was approved in 1995. Today liposomal delivery is established technology used across pharmaceuticals and dietary supplements, with literature spanning thousands of studies on various encapsulated compounds.

A brief history of liposomal delivery

1965

Liposomes first described — Alec Bangham, working at the Babraham Institute in Cambridge, England, observes that phospholipids dispersed in water spontaneously self-assemble into closed bilayer spheres when examined under electron microscopy. The foundational paper that established what we now call liposomes.

1970s

First pharmaceutical delivery research — Researchers begin investigating liposomes as drug carriers. The fundamental rationale: lipid bilayers mimic natural cell membranes, potentially offering a more biocompatible delivery vehicle for therapeutic compounds than aqueous solutions or solid dosage forms.

1980s

Manufacturing scale-up — Industrial methods for producing stable, reproducible liposome formulations are developed. Liposomes find use in cosmetics and topical delivery systems before broader oral nutritional applications.

1995

First FDA-approved liposomal drug — Doxil, a liposomal formulation of the chemotherapy drug doxorubicin, receives FDA approval for the treatment of AIDS-related Kaposi’s sarcoma. The first liposomal pharmaceutical, demonstrating that the format is acceptable to regulators when supported by formulation-specific clinical data.

2000s–present

Liposomal nutraceuticals — Liposomal formulations become widely used in dietary supplements as an alternative to capsule and tablet delivery, particularly for water-soluble vitamins, polyphenols, and other compounds. Bioavailability research varies substantially by molecule; results for one compound do not transfer to another.

Today

Xynaptic Drops™ — Cognizin® citicoline delivered in a liposomal liquid format using sunflower-lecithin bilayer encapsulation. Manufactured by DaVinci Laboratories.

How liposomal delivery works

Liposomal delivery is built on three core properties of phospholipid bilayer chemistry. These are established at the textbook biochemistry level — not speculative or formulation-dependent claims.

Professor 5-Brain explains

Think of a liposome as a tiny lipid bubble that mimics the basic architecture of your own cell membranes. The genius of the design is that the same lipid molecules your body uses to build its cells — phosphatidylcholine — can be used to encapsulate other compounds in a way that feels natural to your biology. With Xynaptic Drops, the lipid carrier (sunflower lecithin) and the active ingredient (Cognizin® citicoline) are biochemically connected: citicoline is the precursor your cells use to make phosphatidylcholine in the first place. There’s an elegant chemistry symmetry between the carrier and the cargo.

Self-assembling bilayers

Phospholipid molecules have a dual nature — hydrophilic heads and hydrophobic tails. In water, they spontaneously arrange into bilayers because the tails minimize their contact with water by clustering together, while the heads remain in contact with water. This is the same physical principle that holds cell membranes together.

Established biophysics

Encapsulation of water-soluble compounds

The interior cavity of a liposome is aqueous (water-filled), which allows water-soluble compounds like citicoline to be encapsulated within it. The lipid bilayer surrounding the cavity provides a physical barrier between the encapsulated compound and the outside environment.

Standard liposome chemistry

Membrane-like biocompatibility

Because liposomes are constructed from the same class of phospholipid that makes up your cell membranes (phosphatidylcholine), they are inherently biocompatible. The body recognizes them as a familiar molecular structure rather than a foreign material.

Established biology

Sunflower lecithin as lipid source

Lecithin is a phospholipid-rich extract that can be derived from sunflower, soy, or egg yolk. Sunflower-derived lecithin is non-GMO and soy-free, making it suitable for those with soy sensitivities. The phosphatidylcholine content of sunflower lecithin provides the structural building block for the liposomal bilayer.

Quality & source transparency

What liposomal delivery is for

Liposomal delivery is one of several established formats for delivering nutraceuticals and pharmaceuticals. Like any format, it has specific use cases where it offers advantages, and others where the simpler formats (capsules, tablets) work fine. Here’s the honest read on what liposomal delivery is well-suited for:

Capsule alternatives

For those who have difficulty swallowing capsules, prefer liquid formats, or who use feeding tubes. A liposomal liquid offers a delivery route that doesn’t require swallowing a solid dosage form.

Dose flexibility

Liquid drops allow individualized dose calibration. With Xynaptic Drops™, 1 mL delivers 250 mg (matching the McGlade 2012 attention trial dose); 2 mL delivers 500 mg cumulative (matching the Nakazaki 2021 memory trial dose).

Lipid-environment compatibility

For compounds where a lipid-rich delivery vehicle is preferred for biochemical or stability reasons. Liposomes mimic the natural lipid environment cells operate in.

Active research area

Liposomal delivery is an active area of pharmaceutical and nutraceutical research. Bioavailability findings vary substantially by molecule — what is established for one compound does not automatically apply to another.

What the research actually says

Honest evidence summary

The liposomal delivery story is genuinely interesting, but it needs to be told carefully because the marketing temptations are significant and the rigorous evidence is more nuanced than supplement industry copy often acknowledges.

What is established: Liposomal delivery is a real, well-characterized lipid-vesicle delivery technology used in both pharmaceuticals (with FDA-approved formulations since 1995) and dietary supplements. The underlying chemistry — phospholipid bilayer self-assembly and encapsulation of water-soluble compounds — is textbook biophysics. Liposomes are biocompatible because they share the same phospholipid composition as natural cell membranes.

What is compound-specific: Bioavailability research on liposomal delivery has been conducted for various molecules — vitamin C, CoQ10, quercetin, glutathione, and others — with varying results. These findings are not transferable between molecules. A bioavailability finding for liposomal CoQ10 says nothing about liposomal citicoline. Each compound has its own absorption profile, and each liposomal formulation has its own characteristics.

What is Cognizin-specific: No published head-to-head clinical trial has directly compared liposomal Cognizin® against capsule Cognizin® for bioavailability or cognitive outcomes in healthy adults. Citicoline itself is already well-absorbed orally — Wurtman et al. 2000 demonstrated that oral CDP-choline produces dose-related, sustained increases in plasma choline and uridine, the precursors used by the brain. The published cognitive research on Cognizin® (McGlade 2012 for attention, Nakazaki 2021 for memory, Silveri 2008 and Babb 2002 for brain imaging) all used capsule formulations, not liposomal.

The honest positioning for liposomal Cognizin® in Xynaptic Drops™: Liposomal delivery is offered as a liquid delivery alternative to capsule Cognizin® — particularly useful for those who do not tolerate capsules, have difficulty swallowing pills, or prefer a liquid format with dose-calibration flexibility. We do not claim that liposomal Cognizin® is more bioavailable than capsule Cognizin®, because no published head-to-head study supports that specific claim.

Why we use liposomal delivery for Xynaptic Drops™

Formulation rationale

Liquid format flexibility. A liposomal liquid format makes Xynaptic Drops™ suitable for those who do not tolerate capsules, have difficulty swallowing pills, or prefer a liquid alternative. The drops format also allows dose calibration: 1 mL = 250 mg Cognizin® (the McGlade 2012 dose), 2 mL = 500 mg (the Nakazaki 2021 / Babb 2002 dose).

Biochemical symmetry. The sunflower lecithin used to construct the liposomal bilayer is itself a source of phosphatidylcholine — the same phospholipid that citicoline is used to build inside cells via the Kennedy pathway. The carrier and the cargo are biochemically related at the molecular level. (See Section 07 for the full chemistry connection.)

Sunflower-derived, soy-free, non-GMO. The lecithin source for the Xynaptic Drops™ liposomes is sunflower-derived rather than soy-derived — suitable for those with soy sensitivities and consistent with the broader Nutropx ingredient-quality standard. The finished product is Vegetarian, Gluten Free, and Soy Free.

Established delivery technology. Liposomal delivery has been used in FDA-approved pharmaceuticals since 1995 and in dietary supplements for over two decades. It is a well-characterized lipid-vesicle technology rather than an experimental format. We use the established technology, with honest framing of what it does and does not establish for Cognizin® specifically.

The chemistry connection

There’s a genuinely elegant biochemistry observation worth highlighting about Xynaptic Drops™: the lipid carrier and the active ingredient are connected at the molecular level. The sunflower lecithin used to build the liposomal bilayer is a source of phosphatidylcholine. And citicoline (CDP-choline) is the obligatory intermediate your cells use to synthesize phosphatidylcholine, via the Kennedy pathway.

Sunflower lecithin

Phosphatidylcholine source

Liposomal bilayer

Encapsulates Cognizin®

Cognizin® citicoline

Builds phosphatidylcholine in cells (Kennedy pathway)

In other words: the same molecular building block (phosphatidylcholine) is used to carry the citicoline in Xynaptic Drops™, and the citicoline goes on to participate in building more phosphatidylcholine once it reaches your cells. This is a real, observable chemistry symmetry between the delivery format and the active ingredient.

Important honest framing: The chemistry connection above is a legitimate observation about the molecular relationship between the carrier and the cargo. It is not a claim that this symmetry produces greater bioavailability, better absorption, or any specific health outcome — those would require head-to-head clinical evidence we do not have. We highlight the chemistry connection because it’s scientifically interesting and reflects a deliberate formulation choice, not as a quantitative performance claim.

Frequently asked questions

Is liposomal Cognizin® more bioavailable than capsule Cognizin®?

No published head-to-head clinical trial has directly compared liposomal Cognizin® against capsule Cognizin® for bioavailability in healthy adults. We do not claim superior bioavailability for the liposomal format because the comparative evidence to support that claim does not exist. Citicoline itself is well-absorbed orally (Wurtman et al. 2000). The liposomal format is offered as a delivery alternative for those who prefer liquids or do not tolerate capsules, not as a bioavailability-superiority claim. If you see liposomal supplement marketing that claims dramatic absorption improvements without citing a head-to-head trial of the specific compound in the product, treat the claim skeptically.

What does “liposomal” actually mean?

A liposome is a microscopic spherical structure made from a phospholipid bilayer — the same kind of molecule (phosphatidylcholine) that makes up natural cell membranes. The liposome has an aqueous (water-filled) interior, which allows water-soluble compounds like citicoline to be encapsulated inside it. Liposomes are typically 50–500 nanometers in diameter — about 1,000 times smaller than a human hair. The bilayer itself is approximately 5 nanometers thick. In Xynaptic Drops™, the Cognizin® citicoline is encapsulated within liposomes built from sunflower lecithin.

Why sunflower lecithin and not soy lecithin?

Lecithin is a phospholipid-rich material that can be derived from sunflower, soy, or egg yolk. We use sunflower-derived lecithin in Xynaptic Drops™ for two reasons: it is suitable for those with soy sensitivities (sunflower lecithin is naturally soy free), and sunflower lecithin is typically non-GMO. The phosphatidylcholine content of sunflower lecithin provides the same lipid bilayer functionality as soy lecithin would, without the soy allergen or GMO concerns. The finished Xynaptic Drops™ product is Vegetarian, Gluten Free, and Soy Free.

Can the liposomal liquid be taken sublingually (under the tongue)?

Xynaptic Drops™ is a liquid format compatible with multiple administration approaches. Per the product instructions, the suggested use is to take 1 mL once or twice daily, shaking well before each use. The published research on Cognizin® was conducted using oral capsule formulations, so we do not make sublingual-specific claims about absorption advantages. For most users, taking the drops orally (with or without water) is the appropriate route.

Why doesn’t Nutropx use the “X% more bioavailable” claims I see on other liposomal supplement labels?

Quantified bioavailability superiority claims (“X% more bioavailable” or “X times faster absorption”) require head-to-head clinical evidence specific to the compound and formulation in the product. Many liposomal supplement labels make such claims based on bioavailability research conducted with different compounds (often CoQ10, vitamin C, or quercetin) and apply those numbers generically to other liposomal products. This is not scientifically supportable. Our policy throughout the Nutropx science section is to make only claims that are directly supported by published research on the specific ingredient and form in our products. For liposomal Cognizin®, no head-to-head bioavailability study has been published, so we do not make quantitative bioavailability claims.

Is liposomal delivery FDA-approved?

The first FDA-approved liposomal pharmaceutical (Doxil) was approved in 1995, demonstrating that liposomal delivery is an acceptable delivery format to the FDA when supported by appropriate clinical data. However, “FDA-approved” in the pharmaceutical sense applies to specific drug formulations that have undergone the FDA new-drug-application process. Xynaptic Drops™ is a dietary supplement, not a pharmaceutical drug. Like all dietary supplements in the United States, it is regulated under the Dietary Supplement Health and Education Act of 1994 (DSHEA), which does not require pre-market FDA approval for safety or efficacy. The Cognizin® citicoline ingredient holds self-affirmed GRAS status (2009) and is authorized as a Novel Food in the European Union.

← All Nutropx ingredient research

References
Bangham AD, Standish MM, Watkins JC (1965) J Mol Biol 13(1):238–52 · PMID 5859039 (foundational liposome paper) · Wurtman RJ, Regan M, Ulus I, Yu L (2000) Biochem Pharmacol 60(7):989–92 · PMID 10974208 (oral citicoline pharmacokinetics) · Babb SM et al. (2002) Psychopharmacology 161(3):248–54 · PMID 12021827 (Cognizin® brain MRS) · Silveri MM et al. (2008) NMR Biomed 21(10):1066–75 · PMID 18816480 (Cognizin® brain bioenergetics) · McGlade E et al. (2012) Food Nutr Sci 3(6):769–73 · DOI 10.4236/fns.2012.36103 (Cognizin® attention) · Nakazaki E et al. (2021) J Nutr 151(8):2153–60 · PMID 33978188 (Cognizin® memory) · Kennedy EP (1956) J Biol Chem (Kennedy pathway, phosphatidylcholine synthesis) · FDA approval Doxil/doxorubicin liposomal (1995, NDA 050718, AIDS-related Kaposi’s sarcoma)

This page is for educational and informational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. For ingredient-specific safety information, dosing, and contraindications, see the Liposomal Citicoline (Xynaptic Drops™) page. Consult your healthcare provider before beginning any supplement regimen. Cognizin® is a registered trademark of Kyowa Hakko Bio Co., Ltd.